$11.05
-0.18-1.6%
最終更新: Oct 14, 4:00 PM
Benzinga
Benzinga
Benzinga
水曜日, 10 14
Benzinga
© 2026 Benzinga | All Rights Reserved
Keros Therapeutics (KROS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.24 | $-0.92 | $-0.47 | $-1.00 |
| Actual | $-1.45 | $-1.21 | $-0.86 | $-0.18 |
| Surprise | -16.9% | -31.5% | -83.0% | +82.0% |
| Revenue | ||||
| Estimate | $635000 | $2.4M | $4.8M | $5.6M |
| Actual | $0 | $367000 | $385000 | $14.3M |
| Surprise | -100.0% | -84.7% | -92.0% | +154.6% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.88 | $-1.77 | $-2.10 | $-2.21 |
| Revenue | ||||
| Consensus | $13.8M | $452856 | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $-1.45 | $-1.24 | -16.9 % |
| Q1 | May 14, 2026 | $-1.21 | $-0.92 | -31.5 % |
| Q4 | Mar 4, 2026 | $-0.86 | $-0.47 | -83.0 % |
| Q3 | Nov 5, 2025 | $-0.18 | $-1.00 | 82.0 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $0 | $635.00K | -100.0 % |
| Q1 | May 14, 2026 | $367.00K | $2.40M | -84.7 % |
| Q4 | Mar 4, 2026 | $385.00K | $4.80M | -92.0 % |
| Q3 | Nov 5, 2025 | $14.26M | $5.60M | 154.6 % |